Pseudomonas aeruginosa Pneumonia (PAP)
AyuVis is developing a new class of drugs to treat complicated respiratory infections such as Pseudomonas aeruginosa pneumonia (PAP) with promising pre-clinical data. PAP is an orphan disease with 50-60,000 cases in the US each year with 13% overall mortality but with multi drug resistant PAP mortality is as high as 28%.
The unmet need for a solution
Pseudomonas aeruginosa pneumonia is a lung infection caused by the bacteria Pseudomonas aeruginosa. It is an opportunistic pathogen because it is capable of attacking its host while the host's immune system is compromised. It is uncommon for healthy individuals to become infected with this organism. PAP is usually a hospital-acquired infection in individuals with weakened immune systems. Pneumonia is considered the largest cause of sepsis (a lethal condition where the body’s own immunity attacks the organs) related deaths in hospitals in US.
The major cause of current treatment failure is due to the increase in antibiotic resistance to bacterial infections. According to the Review on Antimicrobial Resistance:
By the year 2050, deaths from antimicrobial resistant infections are set to skyrocket to 10 million annually.
No new class of antibiotics has been discovered since 1962 for Gram Negative bacteria
There is a continuing unmet need to provide new anti-bacterial agents (that will not develop drug resistance) and/or to develop non-traditional antibiotic therapy that will treat the hyper-inflammation produced by over-reactive immune response to prevent tissue and organ damage, or to restore function and decrease mortality.
Three-Pronged Approach to Treatment
Expected Benefits of AyuVis Compounds:
Lower chance of developing drug resistance
Reduced chance of sepsis
Increased patient survival
Reduced hospital costs
AyuVis is developing a novel small molecule immune-modulating agent that enhances the body’s ability to fight bacterial infection and inflammation when given via intravenous injection (IV) either alone or in combination with existing standard of care antibiotics.
The anti-inflammatory properties differ from current steroids in that they do not suppress but appear to have a synergistic effect on the immune system.
Overall market potential of an AyuVis PAP drug is driven by:
• PAP is growing based on an aging population
• Treatment of PAP adds over $2.4 billion to US healthcare costs each
• PAP currently accounts for $855 million of the $4.5 Billion spent on antibiotics for pneumonia in the US each year
• PAP affects approximately 50-60,000 patients in the US each year
• Effectiveness of antibiotic therapies for PAP are diminishing as multi-drug resistance rises
AyuVis’ proprietary compounds are fundamentally different from other antibiotics. AVR compounds can treat polymicrobial infection using a three-pronged approach:
• Inhibit hyper-inflammation via targeting the host immune response system
• Stimulate the innate immune system, help in microbial clearance, protect organs & repair tissue injury
• Potentiate the anti-bacterial activity of the currently used antibiotics against gram negative bacteria